Generic Eprontia Availability
Last updated on Sep 11, 2024.
Eprontia is a brand name of topiramate, approved by the FDA in the following formulation(s):
EPRONTIA (topiramate - solution;oral)
-
Manufacturer: AZURITY
Approval date: November 5, 2021
Strength(s): 25MG/ML [RLD]
Has a generic version of Eprontia been approved?
No. There is currently no therapeutically equivalent version of Eprontia available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Eprontia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compositions and methods for treating epilepsy, seizures and other conditions
Patent 11,433,046
Issued: September 6, 2022
Inventor(s): Tu Yu-Hsing & Perumal Ashok & Kathala Kalyan & Bhattacharya Romona
Assignee(s): Tulex Pharmaceuticals Inc.Compositions are provided for the liquid oral administration of topiramate and its salts. The invention further provides methods for treating diseases and disorders using the compositions.
Patent expiration dates:
- August 21, 2040✓
- August 21, 2040✓
- August 21, 2040✓
- August 21, 2040
-
Patent 11,633,374
Patent expiration dates:
- August 21, 2040✓
- August 21, 2040
-
Patent 11,826,343
Patent expiration dates:
- August 21, 2040✓
- August 21, 2040
-
Patent 11,911,362
Patent expiration dates:
- August 21, 2040✓✓
- August 21, 2040✓✓
- August 21, 2040✓✓
- August 21, 2040
More about Eprontia (topiramate)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: carbonic anhydrase inhibitor anticonvulsants
- Breastfeeding
- En español
Patient resources
Other brands
Topamax, Trokendi XR, Qudexy XR, Topiragen
Professional resources
Other brands
Topamax, Trokendi XR, Qudexy XR
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
